Join Growin Stock Community!

Exact sciences corporationEXAS.US Overview

US StockHealthcare
(No presentation for EXAS)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

EXAS AI Insights

EXAS Overall Performance

EXAS AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

EXAS Recent Performance

-0.06%

Exact sciences corporation

0.05%

Avg of Sector

-0.31%

S&P500

EXAS PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

EXAS Key Information

EXAS Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

EXAS Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for breast, prostate, and colon cancers; Oncotype Test, a tissue test delivering tumor profiling to aid therapy selection for patients with advanced, metastatic, refractory, or recurrent cancer; Oncotype DX AR-V7 Nucleus Detect Test, a liquid-based test for advanced stage prostate cancer; Oncomap ExTra, that provides a complete biological picture of certain refractory, rare, or aggressive cancers; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research; and Hologic, Inc. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.

Price of EXAS

EXAS FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

EXAS Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-1.09
PE Ratio (TTM)
-
Forward PE
150.35
PS Ratio (TTM)
6.08
PB Ratio
8.21
Price-to-FCF
55.30
METRIC
VALUE
vs. INDUSTRY
Gross Margin
69.69%
Net Margin
-6.40%
Revenue Growth (YoY)
17.69%
Profit Growth (YoY)
17.93%
3-Year Revenue Growth
16.68%
3-Year Profit Growth
14.91%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
-1.09
PE Ratio (TTM)
-
Forward PE
150.35
PS Ratio (TTM)
6.08
PB Ratio
8.21
Price-to-FCF
55.30
Gross Margin
69.69%
Net Margin
-6.40%
Revenue Growth (YoY)
17.69%
Profit Growth (YoY)
17.93%
3-Year Revenue Growth
16.68%
3-Year Profit Growth
14.91%
  • When is EXAS's latest earnings report released?

    The most recent financial report for Exact sciences corporation (EXAS) covers the period of 2025Q4 and was published on 2025/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating EXAS's short-term business performance and financial health. For the latest updates on EXAS's earnings releases, visit this page regularly.

  • What is the operating profit of EXAS?

    According to the latest financial report, Exact sciences corporation (EXAS) reported an Operating Profit of -82.6M with an Operating Margin of -9.4% this period, representing a growth of 90.58% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is EXAS's revenue growth?

    In the latest financial report, Exact sciences corporation (EXAS) announced revenue of 878.38M, with a Year-Over-Year growth rate of 23.12%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much debt does EXAS have?

    As of the end of the reporting period, Exact sciences corporation (EXAS) had total debt of 2.52B, with a debt ratio of 0.43. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does EXAS have?

    At the end of the period, Exact sciences corporation (EXAS) held Total Cash and Cash Equivalents of 956M, accounting for 0.16 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does EXAS go with three margins increasing?

    In the latest report, Exact sciences corporation (EXAS) did not achieve the “three margins increasing” benchmark, with a gross margin of 70.1%%, operating margin of -9.4%%, and net margin of -9.8%%. This demonstrates limited improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess EXAS's profit trajectory and future growth potential.

  • Is EXAS's EPS continuing to grow?

    According to the past four quarterly reports, Exact sciences corporation (EXAS)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at -0.45. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of EXAS?

    Exact sciences corporation (EXAS)'s Free Cash Flow (FCF) for the period is 120.45M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 1,020.74% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of EXAS?

    The latest valuation data shows Exact sciences corporation (EXAS) has a Price-To-Earnings (PE) ratio of -94.77 and a Price/Earnings-To-Growth (PEG) ratio of -0.16. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.